Neuroscientific Biopharmaceuticals Share Price and Company Fundamentals



Price
$0.5
Change
0.060 (13.636%)
52 week
0.2 - 0.505

Last traded: Yesterday at 5:58 AM

NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Cottesloe, Australia.

Key Metrics

PE ratio

-

PB ratio

4.90

Dividend yield

Beta

0.14

Market cap

$71.74M

Enterprise value

$57.57M

Company profile

Primary activitiesBiopharmaceuticals
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.neuroscientific.com
Mailing address85 Forrest Street Suite 5 Nedlands WA 6011 Australia
Phone / Fax61 8 6382 1805 /
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Neuroscientific Biopharmaceuticals does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Neuroscientific Biopharmaceuticals.

NameTitleAgeTotal Pay
Mr. Matthew Liddelow B.Sc.CEO, MD & Director270.69k
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO & Company Sec.70k
Dr. Anton Uvarov Ph.D., BioChem, MBA, MedGenCSO & Exec. Director109.5k
Dr. Alexandra Heaton Ph.D.Director of Operations

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-340.53%

Return on assets

-21.98%

Return on equity

-34.82%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Neuroscientific Biopharmaceuticals is 71.74M and its enterprise value is 57.57M. The enterprise value to revenue ratio of NSB is 60.05.

The NSB's stocks Beta value is 0.14 making it 86% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Neuroscientific Biopharmaceuticals (NSB)

Neuroscientific Biopharmaceuticals (ASX:NSB) Frequently Asked Questions

1. What is Neuroscientific Biopharmaceuticals's Stock Symbol?

Neuroscientific Biopharmaceuticals trades on ASX under the ticker symbol "NSB".

2. What is Neuroscientific Biopharmaceuticals's stock price today?

One share of NSB stock can currently be purchased for approximately $0.5.

3. How can I contact Neuroscientific Biopharmaceuticals?

Neuroscientific Biopharmaceuticals's mailing address is 85 Forrest Street Suite 5 Nedlands WA 6011 Australia. The company can be reached via phone at 61 8 6382 1805.

4. What is Neuroscientific Biopharmaceuticals's official website?

The official website of Neuroscientific Biopharmaceuticals is http://www.neuroscientific.com.

5. Which share registry manages Neuroscientific Biopharmaceuticals's stock?

Neuroscientific Biopharmaceuticals's stock is managed by AUTOMIC REGISTRY SERVICES.